DK3242678T3 - Kombinationspræparater til behandling af cancer eller infektion - Google Patents

Kombinationspræparater til behandling af cancer eller infektion Download PDF

Info

Publication number
DK3242678T3
DK3242678T3 DK16700138.7T DK16700138T DK3242678T3 DK 3242678 T3 DK3242678 T3 DK 3242678T3 DK 16700138 T DK16700138 T DK 16700138T DK 3242678 T3 DK3242678 T3 DK 3242678T3
Authority
DK
Denmark
Prior art keywords
lag
virus
protein
derivative
cancer
Prior art date
Application number
DK16700138.7T
Other languages
English (en)
Inventor
Frédéric Triebel
Chrystelle Brignone
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immutep Sas filed Critical Immutep Sas
Application granted granted Critical
Publication of DK3242678T3 publication Critical patent/DK3242678T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)

Claims (17)

1. Kombinationspræparat, der omfatter: (a) LAG-3-protein, eller et derivat deraf, der kan binde til MHC-klasse-II-molekyler, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domæne Dl, og eventuelt domæne D2, af LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af LAG-3-protein; og (b) en programmeret celledødsprotein-1- (PD-1) banehæmmer, hvor PD-1-banehæmmeren omfatter et anti-PD-1-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, eller hvor PD-1-banehæmmeren omfatter et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1.
2. Farmaceutisk sammensætning, der omfatter: (a) LAG-3-protein, eller et derivat deraf, der kan binde til MHC-klasse-II-molekyler, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domain Dl, og eventuelt domæne D2, af LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af LAG-3-protein; (b) en PD-1-banehæmmer, hvor PD-l-banehæmmeren omfatter et anti-PD-1-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, eller hvor PD-l-banehæmmeren omfatter et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1; og (c) en farmaceutisk acceptabel bærer, excipiens eller fortynder.
3. Kombinationspræparat ifølge krav 1, eller farmaceutisk sammensætning ifølge krav 2, til coadministration eller sekventiel administration af LAG-3-proteinet, eller et derivat deraf, og PD-1 -banehæmmeren.
4. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet, eller et derivat deraf, er adskilt fra PD-1- banehæmmeren.
5. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet, eller et derivat deraf, er til stede i en dosis, der er en molækvivalent af 0,25-30 mg af LAG-3 Ig-fusionsprotein IMP321.
6. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, der omfatter en flerhed af doser af LAG-3-proteinet, eller et derivat deraf og/eller en flerhed af doser af PD-1-banehæmmeren.
7. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor PD-1-banehæmmeren omfatter: et anti-PD-1 -antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, og hvor PD-1-banehæmmeren er pembrolizumab eller nivolumab eller pidilizumab; eller et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1, og hvor PD-1-banehæmmeren er BMS-936559, MED14736, MPDL3280A eller MSB0010718C.
8. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor PD-1-banehæmmeren er til stede ved en dosis, der er op til 50 %, 1-50 %, 1-25 %, eller 1-10 %, af en typisk ordineret dosis af PD-1-banehæmmeren som en monoterapi, eller hvor PD-1-banehæmmeren er til stede ved en dosis, der er 0,1-50 %, 0,1-25 %, 0,1-20 %, 0,1-10 %, <20 %, <10 %, 0,1-<20 %, 0, l-<10 %, 0,01-<20 % eller 0,01-<10 % af en typisk ordineret dosis af PD-1-banehæmmeren som en monoterapi.
9. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet eller et derivat deraf, og PD-1-banehæmmeren, er til stede i en hvilken som helst af kombinationerne af de doseringsmængder, der vises i nedenstående tabel:
10. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domæne Dl, og eventuelt domæne D2, af humant LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af humant LAG-3-protein.
11. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor derivatet af LAG-3-protein er kondenseret til immunoglobulin Fc-sekvensen, fortrinsvis hvor derivatet af LAG-3-protein er det rekombinante opløselige humane LAG-3Ig-fusionsprotein IMP321.
12. Kombinationspræparat eller a farmaceutisk sammensætning ifølge et hvilket som helst af følgende krav til anvendelse som et medikament.
13. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i forebyggelse, behandling eller bedring af cancer.
14. Kombinationspræparat eller farmaceutisk sammensætning til anvendelse ifølge krav 13, hvor canceren er en PD-L1-positiv eller en PD-L2-positiv cancer, eller hvor canceren er hud-, lunge- (navnlig pladeepitel- eller ikke-pladeepitel- ikke-småcellet lungekarcinom, NSCLC), ovarie-, nyre-, colon-, kolorektal-, bryst-, gastrisk, øsofagus-, pankreas-, blære-, urotelial- eller levercancer, eller et melanom (for eksempel, metastatisk malignt melanom), en prostatacancer (for eksempel hormonrefraktært prostataadenokarcinom), cancer i hoved eller hals (for eksempel pladeepitelkarcinom i hoved og hals), en cervixcancer, en thyroideacancer, et glioblastom, et gliom, leukæmi, et lymfom (for eksempel, et B-cellelymfom), en binyrecancer, en aids-associeret cancer, et alveolært bløddelssarkom, en astrocytisk tumor, knoglecancer, en cancer i hjerne og rygmarv, en metastatisk hjernetumor, en karotidlegemetumor, et chondrosarkom, et chordom, et kromofobt nyrecellekarcinom, et spytkirtelkarcinom, kutant benignt fibrøst histiocytom, en desmoplastisk småcellet rund tumor, et ependymom, en Ewings tumor, et ekstraskeletalt myksoidt chondrosarkom, fibrogenesis imperfecta ossium, fibrøst knogledysplasi, en gæIdeblære- eller galdevejscancer, en gestational trofoblastisk sygdom, en kimcelletumor, en hæmatologisk malignitet, et hepatocellulært karcinom, en øcelletumor, et Kaposis sarkom, en nyrecancer, et lipom/en benign lipomatøs tumor, et liposarkom/en malign lipomatøs tumor, et medulloblastom, et meningiom, et Merkelcellekarcinom, en multipel endokrin neoplasi, et multiplet myelom, et myelodysplasisyndrom, et neuroblastom, en neuroendokrin tumor, et papillært thyroideakarcinom, et parathyroideatumor, en pædiatrisk cancer, en perifer nerveskedetumor, et phæochromocytom, en hypofysetumor, en prostatacancer, et posteriori uvealt melanom, en sjælden hæmatologisk forstyrrelse, en metastatisk nyrecancer, en rhabdoid tumor, et rhabdomysarkom, et sarkom, et blødvævssarkom, en pladeepitelcancer, en mavecancer, et synovialsarkom, en testiscancer, et thymuskarcinom, et thymom, en metastatisk thyreoideacancer eller en uteruscancer.
15. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i forebyggelse, behandling eller bedring af en infektion.
16. Kombinationspræparat til anvendelse ifølge krav 15, hvor infektionen er en kronisk eller vedvarende infektion.
17. Kombinationspræparat til anvendelse ifølge krav 15 eller 16, hvor infektionen er en virus-, bakterie-, svampe- eller protozoinfektion, fortrinsvis hvor virusinfektionen er forårsaget af et adenovirus, et adenoassocieret virus, et B-virus (macacine herpesvirus I), et BK-virus, et bunyavirus, et chikungunya-virus, et cocksackie-virus, et coronavirus, et cytomegalovirus, et østligt hesteencephalitis-virus, et ebolavirus, et enterovirus, et Epstein-Barr-virus, et hantavirus, et hepatitis A-virus, et hepatitis B-virus, et hepatitis C-virus, et hepatitis D-virus, et hepatitis E-virus, et herpesvirus, et herpes simplex virus 1, et herpes simplex virus 2, et humant spumavirus, et humant herpesvirus 3, et humant herpesvirus 5, et humant herpesvirus 6, et humant herpesvirus 7, et humant immundefektvirus, et humant papillomavirus, et humant β-lymfotrofisk virus, et humant T-celle-leukæmivirus I, et humant T-celle-leukæmivirus II, et influenzavirus, et JC-virus, et JEV, et Kaposis sarkom-associeret herpesvirus, et Lassa-virus, et lymfocytisk choriomeningitisvirus, et Marburg-virus, et mæslingevirus, et fåresygevirus, et Nipah-virus, et norovirus, et Norwalk-virus, et orthoreovirus, et parainfluenzavirus, et parvovirus, et poliovirus, et rabiesvirus, et reovirus, et respiratorisk syncytialvirus, rhinovirus, et Rift Valley-febervirus, et rotavirus, rubellavirus, et koppervirus, et St Louis encephalitisvirus, et variola major virus, et variola minor virus, et vericella-zoster-virus, et vestnilvirus, et vestligt hesteencephalitis-virus eller et gul febervirus, eller hvor bakterieinfektionen er forårsaget af Escherichia coli, Clostridium difficile, Salmonella thyphimurium, Pseudomonas aeruginosa, Vibrio cholerae, Neisseria gonorrhoeae, Helicobacter pylori, Hemophilus influenzae, Shigella dysenteriae, Staphylococcus aureus, Mycobacterium tuberculosis, Streptococcus pneumonia eller Chlamydia trachomatis, eller hvor svampeinfektionen er forårsaget af Candida, Aspergillus, Cryptococcus, Coccidioides, Histoplasma, Pneumocystis, eller Stachybotrys, eller hvor protozoinfektionen er forårsaget af Amoebozoa, Excavata, Chromalveolata, Entamoeba, Plasmodium, Giardia, Trypanosoma, Coccidia, Besnoitia, Dicrocoelium eller Leishmania.
DK16700138.7T 2015-01-09 2016-01-08 Kombinationspræparater til behandling af cancer eller infektion DK3242678T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500374.2A GB201500374D0 (en) 2015-01-09 2015-01-09 Combined preparations for the treatment of cancer
PCT/EP2016/050321 WO2016110593A1 (en) 2015-01-09 2016-01-08 Combined preparations for the treatment of cancer or infection

Publications (1)

Publication Number Publication Date
DK3242678T3 true DK3242678T3 (da) 2019-03-11

Family

ID=52597438

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16700138.7T DK3242678T3 (da) 2015-01-09 2016-01-08 Kombinationspræparater til behandling af cancer eller infektion
DK18208378.2T DK3473263T3 (da) 2015-01-09 2016-01-08 Kombinerede præparater til behandling af kræft

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18208378.2T DK3473263T3 (da) 2015-01-09 2016-01-08 Kombinerede præparater til behandling af kræft

Country Status (21)

Country Link
US (5) US10874713B2 (da)
EP (3) EP3473263B1 (da)
JP (5) JP7116547B2 (da)
KR (2) KR102704108B1 (da)
CN (2) CN107249619B (da)
AU (3) AU2016205983B2 (da)
CA (1) CA2973044A1 (da)
CY (1) CY1124462T1 (da)
DK (2) DK3242678T3 (da)
ES (2) ES2704272T3 (da)
GB (1) GB201500374D0 (da)
HR (1) HRP20211346T1 (da)
HU (1) HUE055433T2 (da)
IL (1) IL253243A0 (da)
LT (1) LT3473263T (da)
MX (2) MX387326B (da)
PL (2) PL3242678T3 (da)
PT (2) PT3242678T (da)
SI (1) SI3473263T1 (da)
TR (1) TR201901077T4 (da)
WO (1) WO2016110593A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
AU2016379372A1 (en) * 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018048816A1 (en) * 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
WO2019179422A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/lag-3 antibody molecules
MX2021000726A (es) * 2018-07-26 2021-03-25 Bristol Myers Squibb Co Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
WO2020236078A1 (en) * 2019-05-22 2020-11-26 Agency For Science, Technology And Research Pharmaceutical combination
MX2021015448A (es) * 2019-06-14 2022-06-08 G Tech Bio Llc Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
CN110938691B (zh) * 2019-12-03 2023-07-07 兰州大学 人dus4l基因的用途及相关产品
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
MX2022014909A (es) * 2020-05-28 2023-03-06 Immutep Sas Tratamiento del cáncer.
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
GB202108718D0 (en) 2021-06-18 2021-08-04 Immutep Sas Triple combination therapy
US20250282874A1 (en) 2022-05-17 2025-09-11 Suzhou Transcenta Therapeutics Co., Ltd. Bifunctional protein, and preparation thereof and use thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
JPH04504416A (ja) 1989-02-17 1992-08-06 コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． ペプチドの使用方法と合成方法
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US7294712B2 (en) 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69114299T3 (de) 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
JP3459268B2 (ja) 1990-09-17 2003-10-20 中外製薬株式会社 抗癌剤
IE920413A1 (en) 1991-02-08 1992-08-12 Roussel Uclaf Nucleotide sequence coding for ó-chain variable regions of¹human t-lymphocyte receptors, corresponding peptide segments¹and diagnostic and therapeutic applications
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
AU660306B2 (en) 1991-02-12 1995-06-22 Roussel-Uclaf Nucleotidic sequences coding for variable regions of beta chains of human T lymphocyte receptors, corresponding peptidic segments and diagnostic and therapeutic applications
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US6506604B2 (en) 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
ES2281899T3 (es) 1994-05-06 2007-10-01 Institut Gustave Roussy Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo.
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6482925B1 (en) 1996-11-28 2002-11-19 Applied Research Systems Ars Holding N.V. Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
JP3920928B2 (ja) 1996-11-29 2007-05-30 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 移植片拒絶反応の防止法および普遍的遺伝子治療宿主細胞の生産法
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6037177A (en) 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999038954A1 (en) 1998-02-02 1999-08-05 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
AU5544500A (en) 1999-06-15 2001-01-02 Astrazeneca Ab Livin; inhibitor-of-apoptosis protein-3 (iap-3)
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
AT409086B (de) 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
CA2406949A1 (fr) 2000-04-26 2001-11-01 Roger Kravtzoff Utilisation de vecteurs particulaires dans l'immunomodulation
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
CN102342938B (zh) 2002-05-17 2014-08-20 细胞基因公司 用于治疗和控制实体瘤的方法及组合物
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CN1889963A (zh) 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
JP2006124383A (ja) 2004-09-30 2006-05-18 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
JP2006141346A (ja) 2004-11-24 2006-06-08 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20070231298A1 (en) 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009032256A2 (en) 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103347521B (zh) 2010-12-06 2018-05-25 全球癌症治疗有限责任公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
KR20140126357A (ko) * 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
SG11201601763SA (en) * 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
WO2015131176A1 (en) 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Also Published As

Publication number Publication date
SI3473263T1 (sl) 2022-01-31
CN107249619A (zh) 2017-10-13
US20200121757A1 (en) 2020-04-23
US20180271940A1 (en) 2018-09-27
EP3473263B1 (en) 2021-06-02
JP2025109795A (ja) 2025-07-25
CY1124462T1 (el) 2021-12-31
RU2017127000A3 (da) 2019-07-30
EP3242678A1 (en) 2017-11-15
NZ733726A (en) 2024-12-20
JP2024015265A (ja) 2024-02-01
HUE055433T2 (hu) 2021-11-29
EP3943099A1 (en) 2022-01-26
ES2704272T3 (es) 2019-03-15
MX378860B (es) 2025-03-10
KR102704108B1 (ko) 2024-09-10
JP2018506520A (ja) 2018-03-08
PL3473263T3 (pl) 2021-12-13
US20230074746A1 (en) 2023-03-09
AU2016205983A1 (en) 2017-08-03
PL3242678T3 (pl) 2019-05-31
PT3242678T (pt) 2019-02-04
PT3473263T (pt) 2021-08-26
HRP20211346T1 (hr) 2021-11-26
WO2016110593A1 (en) 2016-07-14
MX387326B (es) 2025-03-18
GB201500374D0 (en) 2015-02-25
RU2017127000A (ru) 2019-02-11
US10874713B2 (en) 2020-12-29
CA2973044A1 (en) 2016-07-14
CN114146161A (zh) 2022-03-08
US20230330182A1 (en) 2023-10-19
JP2020073594A (ja) 2020-05-14
JP7565614B2 (ja) 2024-10-11
DK3473263T3 (da) 2021-09-06
IL253243A0 (en) 2017-08-31
KR20240122564A (ko) 2024-08-12
US20210177937A1 (en) 2021-06-17
US10940181B2 (en) 2021-03-09
JP7116547B2 (ja) 2022-08-10
TR201901077T4 (tr) 2019-02-21
JP2022118119A (ja) 2022-08-12
MX2017009003A (es) 2018-03-15
BR112017014742A2 (pt) 2018-02-06
AU2022200133A1 (en) 2022-02-10
AU2016205983B2 (en) 2021-10-28
AU2024204196A1 (en) 2024-07-11
KR20170120104A (ko) 2017-10-30
ES2885901T3 (es) 2021-12-15
MX2021000299A (es) 2021-10-26
CN107249619B (zh) 2021-10-29
NZ771781A (en) 2024-12-20
LT3473263T (lt) 2021-09-27
EP3473263A1 (en) 2019-04-24
US11684654B2 (en) 2023-06-27
EP3242678B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US11684654B2 (en) Combined preparations for the treatment of cancer or infection
Andrews et al. LAG 3 (CD 223) as a cancer immunotherapy target
Jacobs et al. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect
HK40067473A (en) Combined preparations for the treatment of cancer or infection
RU2777945C2 (ru) Комбинированные препараты для лечения рака или инфекции
HK40006950B (en) Combined preparations for the treatment of cancer
HK40006950A (en) Combined preparations for the treatment of cancer or infection
NZ771781A9 (en) Combined preparations for the treatment of cancer or infection
NZ771781B2 (en) Combined preparations for the treatment of cancer or infection
HK1239550A1 (en) Combined preparations for the treatment of cancer or infection
HK1239550B (en) Combined preparations for the treatment of cancer or infection
Shen et al. Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma
BR122024006008B1 (pt) Uso de preparações combinadas e composições para a preparação de medicamento para o tratamento de infecção
BR112017014742B1 (pt) Preparações combinadas para o tratamento de câncer ou infecção
BR122024006008A2 (pt) Preparações combinadas para o tratamento de câncer ou infecção